Using the Merlin assay for reducing sentinel lymph node biopsy complications in melanoma: a retrospective cohort study

BACKGROUND: The assessment of the sentinel lymph node is a cornerstone of melanoma staging. However, ~80% of sentinel lymph node biopsies (SLNB) are negative and nontherapeutic, and patients are unnecessarily exposed to surgery‐related complications. Here, we gauged the potential of the Merlin assay...

Descripción completa

Detalles Bibliográficos
Autores principales: Hieken, Tina J., Sadurní, Mariana B., Quattrocchi, Enrica, Kobic, Ajdin, Sominidi‐Damodaran, Sindhuja, Dwarkasing, Jvalini T., Meerstein‐Kessel, Lisette, Bridges, Alina G., Meves, Alexander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9203934/
https://www.ncbi.nlm.nih.gov/pubmed/35100440
http://dx.doi.org/10.1111/ijd.16056

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9203934/
https://www.ncbi.nlm.nih.gov/pubmed/35100440
http://dx.doi.org/10.1111/ijd.16056

Ejemplares similares